Loading
Pyrotinib is an irreversible pan-ErbB kinase inhibitor pill (EGFR, HER2, HER4) from Jiangsu Hengrui, approved in China since 2018 but not in the US or EU. It is the standard HER2 pill there, given with capecitabine after trastuzumab, and the comparator that new Chinese HER2 ADCs are beating; diarrhoea affects nearly every patient.
Pyrotinib is an irreversible pan-ErbB tyrosine kinase inhibitor covering EGFR, HER2 and HER4, developed by Jiangsu Hengrui. It is China's HER2 pill, widely used there with capecitabine for HER2-positive advanced breast cancer and in the first line with trastuzumab and chemotherapy. PHOEBE (versus lapatinib plus capecitabine) showed PFS of 12.5 versus 6.8 months, and PHILA (first line with trastuzumab plus docetaxel) showed PFS of 24.3 versus 10.4 months. It is approved in China (2018, with 2020s expansions) but not in the US or EU, and diarrhoea is near universal (95% any grade, 31% grade 3 or higher) and drives dose management. It is the control arm of HORIZON-Breast01, where the ADC trastuzumab rezetecan beat pyrotinib plus capecitabine (PFS 30.6 versus 8.3 months). For a newcomer, pyrotinib is the standard HER2 pill in China and the benchmark for the new Chinese HER2 ADCs.
1.Pyrotinib slips into a pocket on HER2.
Sources: NICE search: pyrotinib. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| China | 2018 | HER2+ advanced breast cancer with capecitabine |
| Adverse event | Any grade | Grade 3+ |
|---|---|---|
| Diarrhoea | 95% | 31% |
| Hand-foot syndrome | 60% | - |
Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Pyrotinib" OR ABSTRACT:"Pyrotinib" OR TITLE:"Airuini" OR ABSTRACT:"Airuini") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Pyrotinib, not a curated reading list.
Shares Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway, Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer, HER2, HER2-positive breast cancer.
Shares A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors., HORIZON-Breast01, A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer, HER2-positive breast cancer with brain metastases.
Shares HER2-positive breast cancer with brain metastases, EGFR, HER2, HER2-positive breast cancer.
Shares HER2-positive breast cancer with brain metastases, EGFR, HER2, HER2-positive breast cancer.
Shares A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors, Jiangsu Hengrui Pharmaceuticals, Small-molecule kinase inhibitors.
Shares HER2-positive breast cancer with brain metastases, HER2-positive breast cancer, Small-molecule kinase inhibitors.
Shares HER2-positive breast cancer with brain metastases, HER2-positive breast cancer, Small-molecule kinase inhibitors.
Shares HER2-positive breast cancer with brain metastases, HER2, HER2-positive breast cancer, Small-molecule kinase inhibitors.